AR040145A1 - Compuesto de aminotiofeno y su uso para la preparacion de una composicion farmaceutica - Google Patents

Compuesto de aminotiofeno y su uso para la preparacion de una composicion farmaceutica

Info

Publication number
AR040145A1
AR040145A1 ARP030101991A ARP030101991A AR040145A1 AR 040145 A1 AR040145 A1 AR 040145A1 AR P030101991 A ARP030101991 A AR P030101991A AR P030101991 A ARP030101991 A AR P030101991A AR 040145 A1 AR040145 A1 AR 040145A1
Authority
AR
Argentina
Prior art keywords
alkyl
compound
aminothiophene
diseases
pharmaceutical composition
Prior art date
Application number
ARP030101991A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR040145A1 publication Critical patent/AR040145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

Un compuesto de aminotiofeno que tiene la siguiente fórmula (1) en la que: R1 representa NR4R5; R2 representa CONH2 o SO2NH2; R3 representa hasta tres sustituyentes seleccionados del grupo formado por halógeno, alquilo C1-4, CF3, O-alquilo, S-alquilo, CN; CHO, SO2-alquilo y NO2; R4 representa H o alquilo C1-2; R5 representa C(=A)NHR6, COR7 o R6; A representa O, S o N; R6 representa H o alquilo C1-2; R7 representa alquilo C1-2; L representa un grupo enlazante D-E-D en el que D representa un enlace o alquilo C1-4; E representa -(G)C=C(I)-, CONH, NHCO, COO, N, O, S o s; y G e I representan independientemente H o alquilo C1-2; o una sal farmacéuticamente aceptable de los mismos, con la condición de que el compuesto de fórmula (1) no es 2-[(aminocarbonil)amino]-5-[(4-clorofenil)metil]oxi-3-tiofenocarboxamida. Uso de dicho compuesto para preparar una composición farmacéutica para ser usada en el tratamiento de enfermedades con inhibidores de la fosforilación de la proteína IkB por la enzima IKK-b del tipo de aminotiofenos. Actuando así, estos inhibidores del tipo de aminotiofenos bloquean la activación patológica del factor de transcripción NF-kB en enfermedades en las que está implicada una activación excesiva del NF-kB. Estos compuestos son de aplicación en el tratamiento de trastornos inflamatorios y de separación de tejidos, particularmente artritis reumatoide, asma, enfermedad pulmonar obstructiva crónica, osteartritis, enfermedades autoinmunes, rechazo de tejidos y órganos, enfermedad de Alzheimer, restenosis, diabetes y glomerulonefritis.
ARP030101991A 2002-06-06 2003-06-04 Compuesto de aminotiofeno y su uso para la preparacion de una composicion farmaceutica AR040145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38655602P 2002-06-06 2002-06-06

Publications (1)

Publication Number Publication Date
AR040145A1 true AR040145A1 (es) 2005-03-16

Family

ID=29736177

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101991A AR040145A1 (es) 2002-06-06 2003-06-04 Compuesto de aminotiofeno y su uso para la preparacion de una composicion farmaceutica

Country Status (7)

Country Link
US (1) US7375131B2 (es)
EP (1) EP1532133A4 (es)
JP (1) JP2005531608A (es)
AR (1) AR040145A1 (es)
AU (1) AU2003249683A1 (es)
TW (1) TW200404791A (es)
WO (1) WO2003104218A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
EP1660474B1 (en) 2003-08-15 2008-10-29 AstraZeneca AB Substituted thiophenes and uses thereof
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
WO2006040569A1 (en) * 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US7795306B2 (en) * 2006-03-03 2010-09-14 Inderjit Kumar Dev Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of NF-κB
US20070207989A1 (en) * 2006-03-03 2007-09-06 Savipu Pharmaceuticals Diterpene derivatives for the treatment of cardiovascular, cancer and inflammatory diseases
US7323476B2 (en) * 2006-03-03 2008-01-29 Savipu Pharmaceuticals Myriceric acid derivatives for the treatment of cancer, cardiovascular and inflammatory diseases
US8217037B2 (en) 2006-04-07 2012-07-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
US20070243273A1 (en) * 2006-04-12 2007-10-18 Savipu Pharmaceuticals Reduction of the Deleterious Effects of Tobacco Smoking
US20080017207A1 (en) * 2006-07-18 2008-01-24 Savipu Pharmaceuticals Reduction of the Deleterious Effects of Tobacco Smoking by the Induction of Phase 2 Enzymes by Nerf2
US20080187608A1 (en) * 2007-02-05 2008-08-07 Savipu Pharmaceuticals Enriched fractions from clary sage for the treatment of cancer, cardiovascular and inflammatory diseases
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US20090022821A1 (en) * 2007-07-17 2009-01-22 Inderjit Kumar Dev Compositions from wax myrtle for the treatment of cancer, cardiovascular and inflammatory diseases
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
GB0907120D0 (en) * 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
AU2013279275B2 (en) * 2012-06-22 2017-06-08 Katholieke Universiteit Leuven Novel anti-cancer thiophene compounds
EP3160964B1 (en) 2014-06-27 2024-03-13 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
CN112028884A (zh) * 2020-08-12 2020-12-04 广州瀚信通信科技股份有限公司 一种新型有机化合物及其制备方法和应用
CN112142724A (zh) * 2020-10-15 2020-12-29 广州瀚信通信科技股份有限公司 一种光敏剂及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
CA2119155C (en) 1991-10-18 1999-06-15 Dennis Paul Phillion Fungicides for the control of take-all disease of plants
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
AU2713799A (en) 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
BR9911914B1 (pt) * 1998-07-08 2010-10-19 n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP2002060658A (ja) 2000-08-11 2002-02-26 Fuji Photo Film Co Ltd インクジェット用インク及びインクジェット記録方法
EP1324759A4 (en) 2000-10-12 2004-05-12 Smithkline Beecham Corp NF - G (K) B INHIBITORS
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
JP4544857B2 (ja) * 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
JP2005506334A (ja) * 2001-10-04 2005-03-03 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
TWI281916B (en) * 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
US7196114B2 (en) * 2003-02-17 2007-03-27 Sanofi-Aventis Deutschland Gmbh Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use

Also Published As

Publication number Publication date
EP1532133A4 (en) 2006-11-15
WO2003104218A1 (en) 2003-12-18
JP2005531608A (ja) 2005-10-20
EP1532133A1 (en) 2005-05-25
AU2003249683A1 (en) 2003-12-22
US20050165087A1 (en) 2005-07-28
US7375131B2 (en) 2008-05-20
TW200404791A (en) 2004-04-01

Similar Documents

Publication Publication Date Title
AR040145A1 (es) Compuesto de aminotiofeno y su uso para la preparacion de una composicion farmaceutica
CY1112370T1 (el) Παραγωγα σουλφοναμιδης και χρηση αυτων στη ρυθμιση των μεταλλοπρωτεϊνασων
AR036875A1 (es) Acidos hidroxamicos ciclicos como inhibidores de las metaloproteinasas de matriz y/o de la enzima de conversion del factor de necrosis de tumor alfa
CA2589438C (en) Treatment of inflammatory bowel disease
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
EA200800924A1 (ru) Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
DK1942108T3 (da) Forbindelse indeholdende basisk gruppe samt anvendelse deraf
CO5261605A1 (es) Compustos farmaceuticos
JPWO2004007472A1 (ja) Ｃｃｒ４アンタゴニストおよびその医薬用途
EA200601868A1 (ru) 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
EA200700037A1 (ru) Производные n-гидроксиамида и их применение
RU2006131043A (ru) Соединения силинана в качестве ингибиторов цистеиновой протеазы
AR052841A1 (es) Medicamentos para tratar o prevenir enfermedades fibroticas
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
RU2012131341A (ru) Индол-пиперидинилбензиламины как ингибиторы бета-триптазы
JP2003306481A5 (es)
JP2008543821A5 (es)
MA55199A (fr) Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie
CA2622639A1 (en) Hiv integrase inhibitors
IT1317048B1 (it) Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie
CL2008003378A1 (es) Compuestos derivados de 9,10-dioxo-2-antracen-carboxilico sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de condiciones que son influenciadas por citoquinas pro-inflamatorias de la familia il-1, particularmente enfermedades inflamatorias y autoinmunes.
BRPI0516383A (pt) derivados cìclicos de sulfonil amino e o uso dos mesmos
AR012737A1 (es) Derivados de triptolida utiles en el tratamiento de las enfermedades autoinmunes y usos en la fabricacion de medicamentos
JP2005522492A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal